Silexion Therapeutics (NASDAQ:SLXN) Upgraded at Zacks Research

Zacks Research upgraded shares of Silexion Therapeutics (NASDAQ:SLXN) to a hold rating in a report published on Tuesday,Zacks.com reports.

A number of other research firms have also recently weighed in on SLXN. Litchfield Hills Research started coverage on Silexion Therapeutics in a research report on Monday. They set a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Silexion Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 15th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $75.00.

Silexion Therapeutics Trading Down 5.4%

Shares of Silexion Therapeutics stock opened at $2.43 on Tuesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.97 and a current ratio of 3.97. The company has a market capitalization of $7.61 million, a P/E ratio of -0.22 and a beta of -0.06. Silexion Therapeutics has a 1 year low of $2.13 and a 1 year high of $51.75. The company’s fifty day moving average is $3.01 and its two-hundred day moving average is $6.91.

Silexion Therapeutics (NASDAQ:SLXN) last announced its earnings results on Wednesday, November 12th. The company reported ($2.88) earnings per share for the quarter, topping the consensus estimate of ($3.40) by $0.52.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.